Kuros Biosciences Reports Results for First Half 2023
. Financial Highlights Direct MagnetOs sales increased by 148% from CHF 4.9 million to CHF 12.2 million, total revenue…
. Financial Highlights Direct MagnetOs sales increased by 148% from CHF 4.9 million to CHF 12.2 million, total revenue…
Direct MagnetOs sales climbed from CHF 2.0 million in Q1 2022 to CHF 5.4 million in Q1 2023. Total medical device sales…
Monjuvi® U.S. Netto-Produktumsatz von 23,3 Mio. US-$ (21,7 Mio. €) im zweiten Quartal 2022, ein Wachstum von 25 % im Ver…
- Vorläufiger Monjuvi Netto-Produktumsatz in den USA im zweiten Quartal 2022 in Höhe von 23,3 Mio. US$ (21,7 Mio. €) -…
– Received FDA Clearance to Initiate Twin IMU-838 Phase 3 ENSURE Trials in Relapsing-Remitting Multiple Sclerosis and Su…
Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of select…
Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of select…
Immunic, Inc. (the "Company") (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of select…
EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company” - https://www.commodity-tv.com/...) announces tha…
– Released Very Positive Phase 2 Data for IMU-838 in Relapsing-Remitting Multiple Sclerosis; Company to Submit End-of…